Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment

Status unconfirmed · Early Phase 1

Conditions studied: SARS-CoV-2, Hypoxia, ARDS

In brief

Abstract Background: Clinicians in pulmonary critical care medicine and critical care medicine considered dapsone administration to treat SARS-CoV-2 inflammasome. Dapsone is useful in the molecular regulation of Nod-like receptor family pyrin domain-containing 3 (NLRP3). Objective: To study the targeting of NLRP3 itself or up-/downstream factors of the NLRP3 inflammasome by dapsone must be responsible for its observed preventive effects, functioning as a competitor. Methods: Patients who were on standard COVID-19 therapy are also after obtaining off label uses and explanation of side effects are started on dapsone 100-200 mg daily along with Cimetadine 400 mg three times daily.

Key facts

Study ID
NCT04918914
Run by
Hunt Regional Medical Center
People needed
100
Starts
2020-10-18
Expected to finish
2021-12-31
Last updated by the study team
2021-06-09

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.